LTX-315

01/01/2016 - "Logically, in tumors that were resistant to intratumoral or systemic CTLA4 blockade, subsequent local inoculation of LTX-315 cured the animals or caused tumor regressions with abscopal effects. "
06/01/2014 - "Animals cured by LTX-315 treatment were protected against a re-challenge with live B16 tumor cells both intradermally and intravenously. "
01/01/2021 - "We conducted a phase I dose-escalating study of intratumoral LTX-315 administration in patients with advanced solid tumors. "
09/01/2023 - "Especially, compared with CLB and LTX-315, FXY-3 exhibited significantly increased in vitro cytotoxicity against a panel of cancer cell lines. "
01/01/2022 - "LTX-315 treatment inhibited PD-L1 expression and enhanced lymphocyte infiltration in pancreatic tumors. "

10/27/2015 - "In the present study, we investigated the oncolytic activity of LTX-315 in human melanoma cells (A375). "
10/14/2019 - "Additionally, we show in melanoma that LTX-315 triggers two sequential phases of antitumor response. "
10/01/2021 - "Here, we describe cRGD-functionalized chimaeric polymersomes (cRGD-CPs) as a robust systemic delivery vehicle for LTX-315, which in combination with CpG adjuvant and anti-PD-1 boost immunotherapy of malignant B16F10 melanoma in mice. "
10/14/2019 - "We further show that these CD8+ T cells are involved in suppressing melanoma outgrowth in mice and report similar CD8+ T cell infiltration following LTX-315 treatment in melanoma and sarcoma patients. "
10/14/2019 - "We report LTX-315 mediates profound antitumor effects against Braf- and Pten-driven melanoma and delays the progression of Kras- and P53-driven soft tissue sarcoma in mice. "

06/01/2014 - "In the present study, we investigated the in vivo antitumor effects of LTX-315 against intradermally established B16 melanomas in syngeneic mice. "
06/01/2014 - "Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315."
01/01/2014 - "LTX-315 induced a complete regression of B16 melanomas and systemic protective immune responses following intralesional administration of the peptide."
01/01/2014 - "We have recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, against syngeneic B16 melanomas. "

11/01/2022 - "In this study, we validated the feasibility of using radiofrequency hyperthermia (RFH)-enhanced intratumoral immunochemotherapy of LTX-315 with liposomal doxorubicin for rat orthotopic HCC. "
12/11/2022 - "Methods: For in vitro experiments, VX2 tumor cells were treated with: (1) phosphate buffered saline, (2) radiofrequency hyperthermia (RFH), (3) LTX-315, and (4) RFH plus LTX-315. "

01/01/2022 - "This study aimed to demonstrate the potential effect and mechanism of LTX-315 in PD-L1 inhibition-induced anti-pancreatic cancer immunity. "
01/01/2022 - "ATP11B was identified as a potential target of LTX-315 and a critical regulator in maintaining PD-L1 expression in pancreatic cancer cells. "
01/01/2022 - "Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis."